EWM
LCTX icon

Edge Wealth Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Edge Wealth Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,000
Closed -$3K – 542
2020
Q2 		$3K Hold
4,000
– – ﹤0.01% 592
2020
Q1 		$3K Buy
+4,000
New +$3.98K ﹤0.01% 522

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Edge Wealth Management's LCTX Position: Q3 2020 in Review

Edge Wealth Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2020, closing a stake of 4,000 shares — an estimated $3K sold.

Edge Wealth Management first reported a position in LCTX in Q1 2020 and held it in 2 quarters. The position peaked at $3K in Q2 2020. 76 funds tracked by Wall St. Rank hold LCTX as of Q3 2020.

  • Edge Wealth Management reported no remaining Lineage Cell Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Edge Wealth Management sold 4,000 Lineage Cell Therapeutics shares in Q3 2020, an estimated $3K.
  • Edge Wealth Management first reported a position in Lineage Cell Therapeutics in Q1 2020 and held it in 2 quarters.
  • Edge Wealth Management's Lineage Cell Therapeutics position peaked at $3K in Q2 2020.
  • 76 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2020.

Based on Edge Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.